Abstract:This study aims to test the hypothesis that thiazolidinedione rosiglitazone (RSG), a selective peroxisome proliferator-activated receptor gamma (PPAR gamma) agonist, causes cardiotoxicity independently of PPAR gamma. Energy metabolism and mitochondrial function were measured in perfused hearts isolated from C57BL/6, cardiomyocyte-specific PPAR gamma-deficient mice, and their littermates. Cardiac function and mitochondrial oxidative stress were measured in both in vitro and in vivo settings. Treatment of isolated hearts with RSG at the supratherapeutic concentrations of 10 and 30 mu M caused myocardial energy deficiency as evidenced by the decreases in [PCr], [ATP], ATP/ADP ratio, energy charge with a concomitant cardiac dysfunction as indicated by the decreases in left ventricular systolic pressure, rates of tension development and relaxation, and by an increase in end-diastolic pressure. When incubated with tissue homogenate or isolated mitochondria at these same concentrations, RSG caused mitochondrial dysfunction as evidenced by the decreases in respiration rate, substrate oxidation rates, and activities of complexes I and IV. RSG also increased complexes I- and III-dependent O-2(-) production, decreased glutathione content, inhibited superoxide dismutase, and increased the levels of malondialdehyde, protein carbonyl, and 8-hydroxy-2-deoxyguanosine in mitochondria, consistent with oxidative stress. N-acetyl-L-cysteine (NAC) 20mM prevented RSG-induced above toxicity at those in vitro settings. Cardiomyocyte-specific PPAR gamma deletion and PPAR gamma antagonist GW9662 did not prevent the observed cardiotoxicity. Intravenous injection of 10 mg/kg RSG also caused cardiac dysfunction and oxidative stress, 600 mg/kg NAC antagonized these adverse effects. In conclusion, this study demonstrates that RSG at supratherapeutic concentrations causes cardiotoxicity via a PPAR gamma-independent mechanism involving oxidative stress-induced mitochondrial dysfunction in mouse hearts.

Inhibition of rosiglitazone on NE and PMA induced growth-promoting effects in rat cardiac myocytes in vitro

Inhibition of ET-1 induced growth-promoting effects by Rosiglitazone in cultured rat cardiac myocytes

[Inhibitory Effects of Rosiglitazone Against Endothelin-1-induced Proliferation of Rat Cardiac Myocytes: the Role of PKC-c-fos Pathway].

Rosiglitazone Via Upregulation of Akt/Enos Pathways Attenuates Dysfunction of Endothelial Progenitor Cells, Induced by Advanced Glycation End Products

Effects of Rosiglitazone on Serum Levels of Lipids and Inflammatory Factors in Atherosclerotic Rats

Rosiglitazone ameliorates the dysfunction of endothelial progenitor cells induced by advanced glycation end products

Reverse Effect of Protein Kinase C Inhibitor Ro-31-8220 on the Hypertrophy of Cardiomyocytes of Neonatal Rats Induced by High Glucose Levels

Activation of the endocannabinoid system mediates cardiac hypertrophy induced by rosiglitazone

Protective effect of rosiglitazone on cardiomyocytes injured by ET-1 and its mechanism

Rosiglitazone Inhibits Angiotensin II-Induced Proliferation of Glomerular Mesangial Cells Via the Gαq/Plcβ4/TRPC Signaling Pathway

Cardioprotective effects of acute rosiglitazone treatment

Rosiglitzone Suppresses Angiotensin II-Induced Production of KLF5 and Cell Proliferation in Rat Vascular Smooth Muscle Cells

Activation of peroxisome proliferator-activated receptor gamma inhibits endothelin-1-induced cardiac hypertrophy via the calcineurin/NFAT signaling pathway

Inhibitory effects of rosiglitazone and ciglitazone on rat aortic adventitial fibroblasts proliferation induced by angiotensin Ⅱ in vitro

Effects of rosiglitazone on expressions of peroxisome proliferator-activated receptor gamma and TGF-β1 in rats with adriamycin nephrosis

Rosiglitazone Causes Cardiotoxicity Via Peroxisome Proliferator-Activated Receptor Gamma-Independent Mitochondrial Oxidative Stress In Mouse Hearts

Agonists at PPAR‐γ Suppress Angiotensin II‐induced Production of Plasminogen Activator Inhibitor‐1 and Extracellular Matrix in Rat Cardiac Fibroblasts

Rosiglitazone Inhibits Angiotensin II-induced CTGF Expression in Vascular Smooth Muscle Cells––role of PPAR-γ in Vascular Fibrosis

Rosiglitazone inhibits migration, proliferation, and phenotypic differentiation in cultured human lung fibroblasts.

Adipocyte-specific Loss of PPARγ Attenuates Cardiac Hypertrophy.

Metabonomic Profiling Revealed an Alteration in Purine Nucleotide Metabolism Associated with Cardiac Hypertrophy in Rats Treated with Thiazolidinediones